Nexus Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NEXUS, and what generic alternatives to NEXUS drugs are available?
NEXUS has twenty approved drugs.
There are five US patents protecting NEXUS drugs. There is one tentative approval on NEXUS drugs.
There are ten patent family members on NEXUS drugs in nine countries and eighty-eight supplementary protection certificates in nine countries.
Summary for Nexus
| International Patents: | 10 |
| US Patents: | 5 |
| Tradenames: | 22 |
| Ingredients: | 19 |
| NDAs: | 20 |
Drugs and US Patents for Nexus
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nexus | POTASSIUM CHLORIDE 10MEQ | potassium chloride | INJECTABLE;INJECTION | 214727-001 | Mar 18, 2021 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Nexus Pharms | POTASSIUM CHLORIDE | potassium chloride | INJECTABLE;INJECTION | 217704-001 | Aug 14, 2023 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Nexus Pharms | FLUORESCEIN SODIUM | fluorescein sodium | INJECTABLE;INTRAVENOUS | 215709-002 | Sep 25, 2023 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Nexus | PROCHLORPERAZINE EDISYLATE | prochlorperazine edisylate | INJECTABLE;INJECTION | 204860-001 | Feb 15, 2019 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Nexus | NELARABINE | nelarabine | INJECTABLE;INTRAVENOUS | 215057-001 | Jun 2, 2023 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Nexus Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2022532657 | ⤷ Try a Trial |
| Israel | 288044 | ⤷ Try a Trial |
| Mexico | 2021013888 | ⤷ Try a Trial |
| European Patent Office | 3968975 | ⤷ Try a Trial |
| Canada | 3140043 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Nexus Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0473687 | SPC/GB98/030 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: FOSPHENYTOIN SODIUM (3-HYDROXYMETHYL)-5,5-DIPHENYLHYDANTOIN DISODIUM PHOSPHATE ESTER); REGISTERED: UK 0019/0157 19980204 |
| 0478363 | 48/1999 | Austria | ⤷ Try a Trial | PRODUCT NAME: TIROFIBAN, GEGEBENENFALLS IN DER FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, INSBESONDERE DES HYDROCHLORIDS; NAT. REGISTRATION NO/DATE: 1-23140 UND 1-23141 19990714; FIRST REGISTRATION: LI IKS-NR 54761 19980528 |
| 1718641 | 2012/008 | Ireland | ⤷ Try a Trial | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209 |
| 0480717 | SPC/GB98/025 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: MONTELUKAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY MONTELUKAST SODIUM; REGISTERED: FI 12766 19970825; FI 12767 19970825; UK 00025/0357 19980115; UK 00025/0358 19980115 |
| 3347352 | 2290051-8 | Sweden | ⤷ Try a Trial | PRODUCT NAME: LENACAPAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR LENACAPAVIR SODIUM; REG. NO/DATE: EU/1/22/1671 20220819 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
